RSV Virus-Like Particle Composition for Safe Protective Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective vaccines or antiviral drugs available for Respiratory Syncytial Virus (RSV), which poses a significant global health burden, particularly in children and the elderly, leading to severe complications and infections.
Innovation Solution
Development of virus-like particles (VLPs) comprising RSV M, F, and G proteins, specifically using an RSV platform with M plus P or M plus M2-1, to induce protective immunity against RSV infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine approaches are used, then safety is maintained, but immunogenicity and protective immunity are insufficient
Solution Approach 1:
The patent creates virus-like particles (VLPs) that copy the structural features of infectious RSV viruses without containing the viral genome. These VLPs replicate the external morphology and surface proteins (F, G, M2-1) of authentic viruses, providing immunogenicity through structural mimicry while lacking the genetic material necessary for replication and disease causation, thus achieving safety without sacrificing immunogenicity
Solution Approach 2:
The patent extracts and isolates specific viral proteins (F, G, and M2-1) from the complete virus structure and assembles them into VLPs. By taking out only the essential structural components and eliminating the viral genome, the patent creates an immunogen that provides protective immunity against RSV while removing the harmful replicative capacity of the virus
2Reliability
If existing antiviral drugs are used, then viral replication is inhibited, but treatment effectiveness is limited and resistance develops
Solution Approach 1:
The patent implements preliminary action by inducing protective immunity before RSV infection occurs through vaccination with VLPs. The vaccine prepares the host immune system in advance by generating antibodies and T cells against viral proteins, enabling rapid and effective response upon exposure to the actual virus, thereby preventing infection or severe disease without relying on post-infection drug treatment
3Manufacturing precision
If a complete RSV vaccine is developed, then protective immunity is achieved, but safety concerns arise from viral replication
Solution Approach 1:
The patent creates virus-like particles that copy the external structure and surface proteins of infectious RSV viruses without incorporating the viral genome. These VLPs provide immunogenicity through structural mimicry while lacking the genetic material necessary for replication, thus achieving protective immunity without the harmful effects of viral replication
Solution Approach 2:
The VLPs serve as an intermediary between the infectious virus and the host immune system. They present viral antigens (F, G, M2-1 proteins) to stimulate immune responses without causing infection or replication. The VLPs act as a safe mediator that transfers immunogenic information from the virus to the host without transferring the virus's replicative capacity
Data Source
AI summary
The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection.